Claims for Patent: 7,655,699

Summary for Patent: 7,655,699

Title:	Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
Abstract:	Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and polyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
Inventor(s):	Boehm; Marcus F. (San Diego, CA), Heyman; Richard A. (Encinitas, CA)
Assignee:	Eisai Inc. (Woodcliff Lake, NJ)
Application Number:	08/141,246
Patent Claims:	1. A pharmaceutical composition comprising a compound having the formula: ##STR00031## and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1, formulated for topical administration. 3. The pharmaceutical composition of claim 1, wherein the compound is micronized. 4. The pharmaceutical composition of claim 1, wherein the compound is present in an amount selected from about 5 mg to about 500 mg, and the composition is formulated as a single dosage unit. 5. A pharmaceutical composition comprising a compound having the formula: ##STR00032## and a pharmaceutically acceptable carrier, wherein W is a pharmaceutically acceptable salt selected from among ammonium, sodium, potassium, calcium, magnesium, zinc, lithium, methylamino, dimethylamino, diethylamino and triethylamino salts. 6. The pharmaceutical composition of claim 5, wherein W is sodium or potassium. 7. A method for increasing plasma concentration of high density lipoprotein (HDL) in a mammalian subject, the method comprising administering to the subject an amount of the pharmaceutical composition of claim 1 or claim 5 effective to increase plasma HDL concentration. 8. The method of claim 7, wherein the method is effective to increase the subject's circulating level of apolipoprotein A-1. 9. The pharmaceutical composition of claim 1, formulated for oral administration. 10. A compound having the structure: ##STR00033## or a pharmaceutically acceptable salt thereof. 11. The compound of claim 10, wherein the pharmaceutically acceptable salt is selected from ammonium, sodium, potassium, calcium, magnesium, zinc, lithium, methylamino, dimethylamino, diethylamino and triethylamino salts. 12. The compound of claim 11, wherein the pharmaceutically acceptable salt is selected from sodium and potassium. 13. A method for treating a proliferative disorder in a mammalian subject, the method comprising administering to the mammalian subject an amount of the pharmaceutical composition of claim 1 or claim 5 effective to treat the proliferative disorder, wherein the proliferative disorder is mammary cancer. 14. A method for treating a proliferative disorder in a mammalian subject, the method comprising administering to the mammalian subject an amount of the pharmaceutical composition of claim 1 or claim 5 effective to treat the proliferative disorder, wherein the proliferative disorder is skin cancer. 15. A method for treating a dermatological condition in a mammalian subject, the method comprising administering to the mammalian subject an amount of the pharmaceutical composition of claim 1 or claim 5 effective to treat the dermatological condition, wherein the dermatological condition is psoriasis. 16. A method of activating a retinoid X receptor in a mammalian subject, the method comprising administering to the subject an amount of the pharmaceutical composition of claim 1 or claim 5 effective to activate a retinoid X receptor in the subject. 17. A method of activating a retinoid X receptor in a cell, the method comprising administering to the cell an amount of the pharmaceutical composition of claim 1 or claim 5 effective to activate a retinoid X receptor in the cell.